التفاصيل البيبلوغرافية
العنوان: |
Outcome of hematopoietic stem cell transplantation of children with very high risk acute lymphoblastic leukemia in first complete remission. |
المؤلفون: |
Schechter T; Division of Haematology/Oncology/BMT, Hospital for Sick Children, University of Toronto, ON, Canada. tal.schechter-finkelstein@sickkids.ca, Ishaqi KM, Rojas M, Irina Z, Doyle JJ, Gassas A |
المصدر: |
Pediatric transplantation [Pediatr Transplant] 2010 May; Vol. 14 (3), pp. 377-82. Date of Electronic Publication: 2009 Sep 29. |
نوع المنشور: |
Journal Article |
اللغة: |
English |
بيانات الدورية: |
Publisher: Munksgaard Country of Publication: Denmark NLM ID: 9802574 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1399-3046 (Electronic) Linking ISSN: 13973142 NLM ISO Abbreviation: Pediatr Transplant Subsets: MEDLINE |
أسماء مطبوعة: |
Original Publication: Copenhagen ; Malden, MA : Munksgaard, c1997- |
مواضيع طبية MeSH: |
Hematopoietic Stem Cell Transplantation*, Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy, Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Recurrence ; Remission Induction ; Risk Factors ; Survival Rate ; Transplantation Conditioning/methods ; Treatment Outcome |
مستخلص: |
Approximately 10% of children with ALL present at diagnosis with VHR for relapse if treated with chemotherapy alone. They may benefit from allogeneic HSCT in CR1. We have reviewed the outcome of this population in our institution. Forty-three patients (median age: 8.9 yr) with VHR ALL in CR1 underwent HSCT from October 1994 to April 2006. VHR features included Philadelphia chromosome (n = 17), induction failure (n = 9), hypodiploidy (n = 6), MLL gene rearrangement (n = 5), and others (n = 6). All patients received TBI (1200 cGy) with either CY and/or etoposide. Stem cell source was unrelated (n = 24) and related (n = 19). Incidence of grade III-IV acute GVHD and chronic extensive GVHD were 25% and 16%, respectively. Twelve patients relapsed (eight received related HSCT). Eleven patients died due to transplant-related mortality (eight received unrelated HSCT). For a median follow up of 39 months (range 11-110), the event free survival and OS were 0.49 (95% CI: 0.31-0.67) and 0.53 (CI: 0.44-0.71), respectively. Outcomes of children with VHR ALL receiving HSCT in CR1 remain unsatisfactory. Relapse, mainly after related HSCT, and TRM, mainly after unrelated HSCT, continue to be major problems. |
تواريخ الأحداث: |
Date Created: 20091002 Date Completed: 20100928 Latest Revision: 20100603 |
رمز التحديث: |
20240628 |
DOI: |
10.1111/j.1399-3046.2009.01245.x |
PMID: |
19793223 |
قاعدة البيانات: |
MEDLINE |